23.25

1.19% -0.28

4D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Discussions Forecast

4D Molecular Therapeutics Inc stock is currently priced at $23.25, with a 24-hour trading volume of 321.54K. It has seen a -1.19% decreased in the last 24 hours and a -31.72% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $23.47 pivot point. If it approaches the $22.97 support level, significant changes may occur.

Previous Close:

$23.53

Open:

$23.45

24h Volume:

321.54K

Market Cap:

$1.19B

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-7.0884

EPS:

-3.28

Net Cash Flow:

$-78.56M

1W Performance:

-7.92%

1M Performance:

-31.72%

6M Performance:

+119.34%

1Y Performance:

+13.03%

1D Range:

$22.75

$23.86

52W Range:

$9.44

$36.25

4D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4D Molecular Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

510-505-2680

Address

5858 Horton Street, Suite 455, EmeryVille

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

FDMT's Discussions on Twitter

4D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4D Molecular Therapeutics Inc Stock (FDMT) Latest News

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation

Benzinga

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

GlobeNewswire Inc.

4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Benzinga

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

GlobeNewswire Inc.

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

Zacks Investment Research

4D Molecular Therapeutics Inc Stock (FDMT) Financials Data

4D Molecular Therapeutics Inc (FDMT) Revenue 2024

FDMT reported a revenue (TTM) of $20.72 million for the quarter ending December 31, 2023, a +562.47% rise year-over-year.

4D Molecular Therapeutics Inc (FDMT) Net Income 2024

FDMT net income (TTM) was -$100.84 million for the quarter ending December 31, 2023, a +6.19% increase year-over-year.

4D Molecular Therapeutics Inc (FDMT) Cash Flow 2024

FDMT recorded a free cash flow (TTM) of -$78.56 million for the quarter ending December 31, 2023, a +20.01% increase year-over-year.

4D Molecular Therapeutics Inc (FDMT) Earnings per Share 2024

FDMT earnings per share (TTM) was -$2.66 for the quarter ending December 31, 2023, a +19.88% growth year-over-year.

4D Molecular Therapeutics, Inc. operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase I/II clinical trial for the treatment of fabry disease. It also focuses on developing two investigational new drug candidates, which include 4D-150 for the treatment of wet age-related macular degeneration; and 4D-710 for the treatment of cystic fibrosis lung disease. The company was founded in 2013 and is headquartered in Emeryville, California.